VBI-1901 Emerging Drug Insight and Market Forecast - 2032

VBI-1901 Emerging Drug Insight and Market Forecast − 2032

“VBI-1901 Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about VBI-1901 for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the VBI-1901 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the VBI-1901 for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VBI-1901 market forecast analysis for GBM in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary

VBI-1901 is a cancer vaccine that VBI Vaccines has designed to treat glioblastoma multiforme (GBM) and medulloblastoma, two types of brain tumors. It is designed to kill GBM and medulloblastoma tumor cells infected with cytomegalovirus or CMV. While the immune system already targets cells infected by viruses, VBI-1901’s goal is to boost their immune response to such viruses. CMV inside tumor cells generates proteins called viral antigens that travel to the cells’ surface. It is developed to coax the body to produce antibodies and white blood cells that can kill tumor cells with these antigens. The vaccine does not contain the live virus but consists of tiny particles called envelopes that contain two kinds of CMV proteins. The particles themselves cannot cause an infection. The immune system recognizes the CMV-generated proteins as foreign to the body and mounts a response against them. Because the proteins are on the surface of tumor cells, the immune system eliminates the tumor cells, too. VBI-1901 also includes a protein called granulocyte-macrophage colony-stimulating factor that gives the vaccine more strength. It spurs its ability to trigger an immune response by attracting immune dendritic cells to the site where the vaccine is injected.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the VBI-1901 description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).

Elaborated details on VBI-1901 regulatory milestones and other development activities have been provided in this report.

The report also highlights the VBI-1901 research and development activities in GBM across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around VBI-1901.

The report contains forecasted sales of VBI-1901 for GBM till 2032.

Comprehensive coverage of the late-stage emerging therapies for GBM.

The report also features the SWOT analysis with analyst views for VBI-1901 in GBM.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VBI-1901 Analytical Perspective by DelveInsight

In-depth VBI-1901 Market Assessment

This report provides a detailed market assessment of VBI-1901 for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

VBI-1901 Clinical Assessment

The report provides the clinical trials information of VBI-1901 for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VBI-1901 dominance.

Other emerging products for GBM are expected to give tough market competition to VBI-1901 and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VBI-1901 in GBM.

Our in-depth analysis of the forecasted sales data of VBI-1901 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VBI-1901 in GBM.

Key Questions

What is the product type, route of administration and mechanism of action of VBI-1901?

What is the clinical trial status of the study related to VBI-1901 in glioblastoma multiforme (GBM) and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VBI-1901 development?

What are the key designations that have been granted to VBI-1901 for GBM?

What is the forecasted market scenario of VBI-1901 for GBM?

What are the forecasted sales of VBI-1901 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to VBI-1901 for GBM?

Which are the late-stage emerging therapies under development for the treatment of GBM?